Based on results from phase 3 studies called SONICS and LOGICS, the FDA approved the drug for adults with Cushing’s syndrome. Xeris picked up Recorlev earlier this year in its acquisition of rare disease biotech Strongbridge Biopharma. It's planning to launch in the first quarter of 2022.
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdings, Inc. (“Xeris Biopharma Holdings”). Strongbridge shares and Xeris shares ceased trading on the Nasdaq Global Select Market (“Nasdaq”) at the close of business today. Shares of Xeris Biopharma Holdings are expected to begin trading on the Nasdaq under the ticker symbol “XERS” on October 6, 2021.
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the “Court”) has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (“Xeris”) by means of scheme of arrangement (the “Scheme”) under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Act”).
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) (“Strongbridge”) by Xeris.
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (“Xeris”). As described below, at least 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the “Court Meeting”) and at an extraordinary general meeting of shareholders (the “EGM”) were in favor of the transaction, representing (in each case) approximately 67 percent of the shares outstanding and eligible to be voted at each of the Strongbridge shareholder meetings held on September 8, 2021 in Pennsylvania, United States of America. Upon close of the transaction, the business of Xeris and Strongbridge will be combined under an entity called Xeris Biopharma Holdings, Inc. (“Xeris Biopharma Holdings” or “HoldCo”).
Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge” or the “Company”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today reported financial results for the second quarter of 2021 and provided a corporate update.
Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the “Irish Takeover Rules”), that the definitive joint proxy statement/prospectus of Strongbridge (the “Proxy Statement”),Â
Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will report the Company’s second quarter 2021 financial results and corporate highlights on August 5, 2021 at 7:30 a.m. ET.
Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced in accordance with Rule 2.10 of the Irish Takeover Rules that, as of the close of business on July 28, 2021,